These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 19955909)
1. Proteomic profiling in ovarian cancer. Kim G; Minig L; Kohn EC Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2(Suppl 2):S2-6. PubMed ID: 19955909 [TBL] [Abstract][Full Text] [Related]
2. Proteomics as a guiding tool for more effective personalized therapy. Lee JM; Kohn EC Ann Oncol; 2010 Oct; 21 Suppl 7(Suppl 7):vii205-10. PubMed ID: 20943616 [TBL] [Abstract][Full Text] [Related]
3. A proteomic signature of ovarian cancer tumor fluid identified by highthroughput and verified by targeted proteomics. Poersch A; Grassi ML; Carvalho VP; Lanfredi GP; Palma CS; Greene LJ; de Sousa CB; Carrara HHA; Candido Dos Reis FJ; Faça VM J Proteomics; 2016 Aug; 145():226-236. PubMed ID: 27222041 [TBL] [Abstract][Full Text] [Related]
4. Increased WD-repeat containing protein 1 in interstitial fluid from ovarian carcinomas shown by comparative proteomic analysis of malignant and healthy gynecological tissue. Haslene-Hox H; Oveland E; Woie K; Salvesen HB; Wiig H; Tenstad O Biochim Biophys Acta; 2013 Nov; 1834(11):2347-59. PubMed ID: 23707566 [TBL] [Abstract][Full Text] [Related]
5. Proteomics of ovarian cancer: functional insights and clinical applications. Elzek MA; Rodland KD Cancer Metastasis Rev; 2015 Mar; 34(1):83-96. PubMed ID: 25736266 [TBL] [Abstract][Full Text] [Related]
6. Predictive modeling in proteomics-based disease detection. Pham TD Annu Int Conf IEEE Eng Med Biol Soc; 2007; 2007():3308-11. PubMed ID: 18002703 [TBL] [Abstract][Full Text] [Related]
7. Quantitative Mass Spectrometry-Based Proteomics for Biomarker Development in Ovarian Cancer. Ryu J; Thomas SN Molecules; 2021 May; 26(9):. PubMed ID: 34063568 [TBL] [Abstract][Full Text] [Related]
8. Ovarian cancer: can proteomics give new insights for therapy and diagnosis? Toss A; De Matteis E; Rossi E; Casa LD; Iannone A; Federico M; Cortesi L Int J Mol Sci; 2013 Apr; 14(4):8271-90. PubMed ID: 23591842 [TBL] [Abstract][Full Text] [Related]
9. Profiling signatures of ovarian cancer tumour suppression using 2D-DIGE and 2D-LC-MS/MS with tandem mass tagging. Sinclair J; Metodieva G; Dafou D; Gayther SA; Timms JF J Proteomics; 2011 Apr; 74(4):451-65. PubMed ID: 21237297 [TBL] [Abstract][Full Text] [Related]
10. Ovarian cancer in the proteomics era: diagnosis, prognosis, and therapeutics targets. Boyce EA; Kohn EC Int J Gynecol Cancer; 2005; 15 Suppl 3():266-73. PubMed ID: 16343243 [TBL] [Abstract][Full Text] [Related]
11. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Jones MB; Krutzsch H; Shu H; Zhao Y; Liotta LA; Kohn EC; Petricoin EF Proteomics; 2002 Jan; 2(1):76-84. PubMed ID: 11788994 [TBL] [Abstract][Full Text] [Related]
12. Proteomics and ovarian cancer: implications for diagnosis and treatment: a critical review of the recent literature. Posadas EM; Davidson B; Kohn EC Curr Opin Oncol; 2004 Sep; 16(5):478-84. PubMed ID: 15314519 [TBL] [Abstract][Full Text] [Related]
13. Novel proteomic technologies to address gaps in pre-clinical ovarian cancer biomarker discovery efforts. Jordan HA; Thomas SN Expert Rev Proteomics; 2023; 20(12):439-450. PubMed ID: 38116719 [TBL] [Abstract][Full Text] [Related]
14. Ovarian Cancer Biomarkers: Moving Forward in Early Detection. Bonifácio VDB Adv Exp Med Biol; 2020; 1219():355-363. PubMed ID: 32130708 [TBL] [Abstract][Full Text] [Related]
15. Ovarian cancer in the proteomics era. Annunziata CM; Azad N; Dhamoon AS; Whiteley G; Kohn EC Int J Gynecol Cancer; 2008; 18 Suppl 1():1-6. PubMed ID: 18336391 [TBL] [Abstract][Full Text] [Related]
16. Identification and validation of salivary proteomic signatures for non-invasive detection of ovarian cancer. Tajmul M; Parween F; Singh L; Mathur SR; Sharma JB; Kumar S; Sharma DN; Yadav S Int J Biol Macromol; 2018 Mar; 108():503-514. PubMed ID: 29222021 [TBL] [Abstract][Full Text] [Related]
17. Clinical application of proteomics in ovarian cancer prevention and treatment. Meani F; Pecorelli S; Liotta L; Petricoin EF Mol Diagn Ther; 2009; 13(5):297-311. PubMed ID: 19791834 [TBL] [Abstract][Full Text] [Related]
18. Proteomic biomarkers for ovarian cancer risk in women with polycystic ovary syndrome: a systematic review and biomarker database integration. Galazis N; Olaleye O; Haoula Z; Layfield R; Atiomo W Fertil Steril; 2012 Dec; 98(6):1590-601.e1. PubMed ID: 22959458 [TBL] [Abstract][Full Text] [Related]